

## Annex A: Amended AVMA Key Terms

This Annex provides an updated overview of key terms of the AVMA approved by the Gavi Board (*Board-2024-Mtg-02-Doc 11b-Annex A: AVMA Base Proposal*) which themselves were updated from (*Board-2023-Mtg-04-Doc 10b - Annex A: AVMA Key Terms*).

2025 Updates are shown in **bold underline**, and are restricted to three additions to the list of priority vaccines overleaf.

Design element	Proposal
<b>Size</b>	Funding requirement of US\$ 750-1,000 million – with the upper end of the range set to accommodate an ambitious outcome for African products in terms of number of incentivised manufacturers and their commercial volumes
<b>Scope</b>	All Gavi Alliance supported vaccines (with differences in payments, see “Incentives”), fill & finish-only (i.e. drug product), and “end-to- end” drug substance + drug product.
<b>Duration</b>	To be <u>launched in June 2024</u> with a proposed duration of 10 years (payments can continue for a period beyond the 10-year mark, depending on tender lengths) <sup>1</sup>
<b>Eligibility</b>	<p>Vaccine Type: Qualifying Vaccine that is WHO Prequalified</p> <p>Manufacturing Type:</p> <ul style="list-style-type: none"> <li>i) The Qualifying Vaccine is Fully Manufactured on the African continent;</li> <li>or</li> <li>ii) Fill &amp; Finish of the Qualifying Vaccine is carried out in a manufacturing facility on the African continent that is Controlled by the holder of the WHO Pre- Qualification of the Qualifying Vaccine.</li> </ul>
<b>Procurement pathway</b>	<p>Via successful Gavi-UNICEF tenders and fulfil all other eligibility criteria</p> <p>A potential AU pooled procurement mechanism may be accommodated in the future, subject to determination in line with AVMA’s governance arrangements)</p>
<b>Incentives</b>	<p>Structure</p> <ul style="list-style-type: none"> <li>• Milestone payment at WHO Prequalification</li> <li>• Per-dose accelerator payment, paid per dose, upon delivery of UNICEF tender</li> </ul>

---

Priorities	<p>Platforms: mRNA &amp; Viral Vector ('rapid response platforms')</p> <p>Vaccines:</p> <ul style="list-style-type: none"> <li>• Oral Cholera Vaccine</li> <li>• Malaria</li> <li>• Measles-Rubella (MR)</li> <li>• Hexavalent (wP)</li> <li>• Yellow Fever</li> <li>• Pneumococcal (required profile: min. 13 valent)</li> <li>• Ebola (required profile: indication against 2+ Ebola species and thermostable from -20C)</li> <li>• Rotavirus (required profile: single-dose blow-fill-seal presentation)</li> <li>• <b><u>Novel Tuberculosis (TB)</u></b></li> <li>• <b><u>Maternal Respiratory Syncytial Virus (RSV)</u></b></li> <li>• <b><u>Mpox (required profile: age 2 years, single dose regimen)</u></b></li> </ul>
Values	<p><b>Milestone payment</b></p> <ul style="list-style-type: none"> <li>• USD 25 million: drug substance manufactured on Priority platform</li> <li>• USD 20 million: drug substance for Priority vaccine</li> <li>• USD 10 million: drug product for Priority vaccine ("fill and finish only")</li> </ul> <p><b>Accelerator payment</b></p> <ul style="list-style-type: none"> <li>• USD 0.50 per dose: drug substance manufactured on Priority platform</li> <li>• USD 0.50 per dose: drug substance for Priority vaccine</li> <li>• USD 0.40 per dose: all other Gavi-supported drug substance</li> <li>• USD 0.30 per dose: for Gavi-supported drug product (i.e., "fill and finish only") up to a cap of USD 1 per vial</li> </ul>
Caps	<ul style="list-style-type: none"> <li>• The total disbursement (Milestone and Accelerator payments across the entire instrument is capped at:</li> <li>• Net funds raised for the AVMA initiative, after deducting operational costs<sup>5</sup></li> <li>• USD 300 million per vaccine (pathogen) category / market</li> <li>• USD 250 million for Milestone payments</li> <li>• USD 250 million for "fill and finish only"</li> <li>• The total disbursement (Milestone and Accelerator payments) per manufacturer is capped at:</li> <li>• USD 250 million, of which, USD 50 million for "fill and finish only"</li> </ul>

---